Advancing Science. Improving Connections.

Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.

Our People

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare conditions

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

05.23

Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Read More
05.15

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

Read More
04.12

Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference

Read More
04.05

Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference

Read More

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

You are now leaving the Zynerba website

You are being redirectd to a third-party website. The terms and conditions of this third-party website may be different from zynerba.com and will govern your use of such website.

Continue (5) Cancel